5 Key Takeaways
-
1
Sura-vec (ABBV-RGX-314) is a gene therapy for nonproliferative diabetic retinopathy delivered via a one-time injection.
-
2
In the ALTITUDE phase 2 trial, dose levels 2 and 3 showed a significant reduction in worsening DRSS scores compared to the control group.
-
3
At year 3, 60% of patients in dose level 3 experienced a 2-step-or-greater DRSS improvement, with no worsening in the control group.
-
4
Safety data indicated no serious adverse events related to sura-vec, with mild cases of ocular hypertension and episcleritis reported.
-
5
The NAAVIGATE phase 2b/3 clinical trial is currently enrolling participants to further evaluate the efficacy of sura-vec.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.